News
Merck Completes Enrollment in Pivotal Phase 3 “EPOCH” Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer’s Disease
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today confirmed the completion of enrollment for the EPOCH trial, a Phase...
Press Releases
Changes to the Roche Corporate Executive Committee
Silvia Ayyoubi (62), Head of Group Human Resources for Roche and member of the Corporate Executive Committee has decided to retire from Roche following...
Press Releases
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NSYE:PFE) today announced that the companies have entered into a collaboration agreement with Portola Pharmaceuticals Inc. (Nasdaq:...
Press Releases
Bristol-Myers Squibb Foundation Awards Eight Grants Totaling Nearly $11.5M to Make Lung and Skin Cancer Screening, Care More Accessible in High-Risk U.S. Communities
"The grant from the Bristol-Myers Squibb Foundation will allow us the opportunity to better reach and inform these at-risk patients in our area and...
Techno Trends
Novartis Access
The menace of noncommunicable diseases (NCDs) like cardiovascular diseases, diabetes and cancer in the developing world is increasing. These conditions disproportionally affect poverty-stricken areas....
Industry Reports
INNATE PHARMA IN-LICENSES OREGA BIOTECH’S FIRST-IN-CLASS ANTI-CD39 CHECKPOINT INHIBITOR PROGRAM
This program, currently in preclinical development, aims at developing an anti-CD39 mAb; Targeting the adenosine immunosuppressive pathway has potential to promote anti-tumor immune...
Research Insight
SINE™ Technology
A human cell is divided into various compartments, including the nucleus and the cytoplasm. The nucleus contains a cell’s genetic material, or DNA, and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read